{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-23-000088","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.699510+00:00","generated_at":"2026-06-07T15:02:10.483128+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"low","headline":"Tarsus announces positive topline Phase 2a results for TP-03 in MGD with Demodex mites","bullets":["Ersa trial evaluated TP-03 (lotilaner ophthalmic solution, 0.25%) BID or TID for 12 weeks.","Trial enrolled Meibomian Gland Disease patients with Demodex mites.","Company states positive topline results; detailed data presented in corporate deck.","No specific efficacy or safety numbers disclosed in the 8-K filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-23-000088","json":"https://secwatch.observer/filing/0001819790-23-000088.json","markdown":"https://secwatch.observer/filing/0001819790-23-000088.md","text":"https://secwatch.observer/filing/0001819790-23-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/0001819790-23-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979023000088/tars-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:02:10.483128+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}